SciGen : SALE OF INTEREST IN INDIAN SUBSIDIARY

ASX Announcement and Media Release

Friday 27 June 2014

SciGen Ltd

The Board of Directors of SciGen Limited (ASX : SIE) (the "SciGen") are pleased to announce the conclusion of an Agreement for the sale of its total interest amounting to 50.01% of the equity of SciGen BioPharma Pvt Ltd ("SBPL") to Anglo Gulf FZE ("AGF") for a cash consideration of US$7 million. ("Transaction"). This sale is conditional upon the fulfilment of conditions precedent by 15 August 2014 and also includes the approval of SIE shareholders.
SBPL is a joint venture company established in India for the manufacture of human insulin. As of today, the manufacturing facility is not yet operational. As SciGen's holding company, a major manufacturer of human insulin, has sufficient capacity to meet all of SciGen's requirements for years to come, the Board of Directors see no current need for any further investment in a manufacturing facility and have approved the disposal of SBPL.
AGF, a company incorporated in the United Arab Emirates is a part of the Indian MJ Group which has more than 30 years presence in the pharmaceutical industry and extensive experience in the development, sales and marketing of biotechnology derived and other pharmaceutical products.
This Transaction, subject to the approval and consents of all relevant authorities is also subject to SciGen's shareholders approval for the purpose of ASX Listing Rule 10.1. The Notice of Extraordinary General Meeting for the approval of this transaction will be sent out in due course.

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes therapeutics such as rhuman Growth Hormone, rhuman Insulin and GCSF.
SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster

Telephone : + 61 2 9485 1800 Facsimile : + 61 2 9485 1888 Website: www.scigenltd.com
entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.
SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.
SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.
SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, China, and India, distribution channels in China, India, Indonesia, Malaysia, Myanmar, Pakistan, Philippines, Thailand and Vietnam, manufacturing facility in India and a contract manufacturer
in Poland, Bioton S.A.

Telephone : + 61 2 9485 1800 Facsimile : + 61 2 9485 1888 Website: www.scigenltd.com

distributed by